このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Jiangsu Kanion PharmaceuticalLtd マネジメント

マネジメント基準チェック /34

Jiangsu Kanion PharmaceuticalLtd'sの CEO はYongchun Yangで、 Apr2021年に任命され、の在任期間は 3.17年です。は、会社の株式の0.052%を直接所有しており、その価値はCN¥ 5.19M 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と2.6年です。

主要情報

Yongchun Yang

最高経営責任者

CN¥758.6k

報酬総額

CEO給与比率	n/a
CEO在任期間	3.5yrs
CEOの所有権	0.04%
経営陣の平均在職期間	2.2yrs
取締役会の平均在任期間	2.9yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Yongchun Yang (51 yo)

3.5yrs

在職期間

CN¥758,600

報酬

Mr. Yongchun Yang is General Manager at Jiangsu Kanion Pharmaceutical Co. Ltd. since April 9, 2021 and has been its Director since December 27, 2019. Mr. Yang served as Chief Marketing Officer and Deputy G...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Yongchun Yang	GM & Director	3.5yrs	CN¥758.60k	0.036% CN¥ 2.9m
Suocheng Jiang	Deputy Chief Accountant	1.8yrs	CN¥207.50k	0.0043% CN¥ 349.6k
Feipeng Xian	Deputy General Manager	1.3yrs	CN¥521.10k	0.0069% CN¥ 559.0k
Haixin Gao	Board Secretary & Director	less than a year	CN¥1.05m	0.024% CN¥ 2.0m
Quan Liu	Deputy General Manager	4.8yrs	CN¥742.70k	0.024% CN¥ 2.0m
Yu Pan	Deputy GM & Market Development Center	2.6yrs	CN¥1.07m	0.024% CN¥ 2.0m
Yun Wu	Deputy General Manager	1.3yrs	CN¥637.00k	0.018% CN¥ 1.5m
Chuanlei Wang	Deputy General Manager	2.6yrs	CN¥710.40k	0.024% CN¥ 2.0m

2.2yrs

平均在職期間

46yo

平均年齢

経験豊富な経営陣: 600557の経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Yongchun Yang	GM & Director	4.8yrs	CN¥758.60k	0.036% CN¥ 2.9m
Haixin Gao	Board Secretary & Director	1.3yrs	CN¥1.05m	0.024% CN¥ 2.0m
Wei Xiao	Chairman	23.9yrs	CN¥2.39m	2.95% CN¥ 237.7m
Zhenzhong Wang	Vice Chairman of the Board	8.1yrs	CN¥1.03m	0.036% CN¥ 2.9m
Meiling Jiang	Supervisor	1.3yrs	データなし	データなし
Min Xu	Independent Director	3.4yrs	CN¥100.00k	データなし
Kaixian Chen	Independent Director	4.8yrs	CN¥100.00k	データなし
Wu Di	Supervisor	2.4yrs	データなし	データなし
Xuebin Chen	Director	1.3yrs	CN¥641.10k	0.0097% CN¥ 782.9k
Lin Jiang	Supervisor	1.3yrs	データなし	データなし

2.9yrs

平均在職期間

47.5yo

平均年齢

経験豊富なボード: 600557の取締役会は経験豊富ではない ( 2.6年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Jiangsu Kanion PharmaceuticalLtd マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Jiangsu Kanion Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 02, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 2Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Jul 27, 2024

First quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.25 in 1Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 13, 2024

Investor sentiment improves as stock rises 18%

Jiangsu Kanion Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 02, 2024

Full year 2023 earnings released: EPS: CN¥0.93 (vs CN¥0.75 in FY 2022)

Now 20% undervalued after recent price drop

Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) announces an Equity Buyback for CNY 150 million worth of its shares.

Investor sentiment deteriorates as stock falls 17%

Now 23% undervalued after recent price drop

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 11, 2024

New minor risk - Share price stability

Now 20% undervalued

Third quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 2Q 2022)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Jul 13, 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.19 in 1Q 2022)

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.75 (vs CN¥0.56 in FY 2021)

Investor sentiment improves as stock rises 18%

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.081 in 3Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.14 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.081 (vs CN¥0.08 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.10 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.86 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: CN¥9.43

New 90-day low: CN¥10.99

New 90-day low: CN¥12.14

Third quarter earnings released

New 90-day low: CN¥12.29

New 90-day low - CN¥12.67

New 90-day low - CN¥12.93

First half earnings released

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34